Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

In “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study,” Bar-Or et al. demonstrated a significant reduction in the number of new brain lesions in patients who were given ofatumumab compared with those who received placebo. However, Dr. Kearney notes that comparing ofatumumab to placebo, rather than a disease-modifying therapy, could have artificially inflated the benefit of ofatumumab.

Source link

Related posts

Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson disease


Cortical superficial siderosis: A prospective observational cohort study


Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World